文献速递造血干细胞移植与细胞治疗

HLA单倍体相合造血干细胞移植治疗慢性肉芽肿病:一项EBMT-IEWP回顾性研究

HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study.
PubMed 文献 · Blood · 2025-01-01

该多中心回顾性研究分析64例慢性肉芽肿病(CGD)患者接受HLA单倍体相合家族供者首次造血干细胞移植的结局,采用体外TCRαβ/CD19去除或移植后环磷酰胺体内去除。全队列3年总生存率75.9%、无事件生存率70.2%、无3-4级GVHD的无事件生存率56.1%,原发移植失败累积发生率20.6%。作者认为HLA单倍体相合移植是缺乏HLA相合供者CGD患者的可行移植选择,需进一步优化方案以减少移植失败和急性GVHD。

要点

  • 64例CGD患者接受HLA单倍体相合移植,3年总生存率75.9%、无事件生存率70.2%。
  • 原发移植失败累积发生率20.6%,3-4级GVHD-free无事件生存率56.1%。
  • PTCY组2-4级急性GVHD累积发生率更高(P = .04),3-4级GVHD无差异。

核心结论

  • HLA单倍体相合造血干细胞移植是缺乏HLA相合供者CGD患者的可行移植选择。
  • 需进一步优化移植方案以减少移植失败和急性GVHD,从而改善该挽救性治疗的可及性和结局。

研究设计与样本

  • EBMT-IEWP开展的回顾性多中心研究,分析64例CGD患者(53例男性;46例X连锁CGD)接受HLA单倍体相合家族供者首次造血干细胞移植的结局。
  • 移植采用体外T细胞受体(TCR)αβ/CD19去除或移植后环磷酰胺(PTCY)体内去除。
  • 移植时平均年龄5.8岁(范围0-33岁)。

主要发现

  • 移植前疾病负担高:45%患者在移植前6个月内发生感染,67%患者存在炎症。
  • 全队列3年总生存率为75.9%,无事件生存率(EFS)为70.2%,无3-4级移植物抗宿主病(GVHD)的EFS为56.1%,且不受去除方式或年龄影响。
  • 原发移植失败(PGF)的累积发生率为20.6%。
  • PTCY组2-4级急性GVHD累积发生率更高(P = .04),而3-4级GVHD累积发生率无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic granulomatous disease (CGD) is an inborn error of immunity characterized by defective NAD phosphate oxidase function, leading to impaired microbial killing, recurrent infections, and granulomatous inflammation. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for CGD, particularly effective when a fully HLA-matched donor is available. However, the place of HLA-haploidentical HSCT remains less established. This retrospective multicenter study analyzed outcomes of 64 patients with CGD (53 males; 46 with X-linked CGD) who underwent a first HSCT with HLA-haploidentical family donors, with either in vitro T-cell receptor (TCR)αβ/CD19 depletion or in vivo depletion using posttransplant cyclophosphamide (PTCY). The mean age at transplant was 5.8 years (range, 0-33). Patients exhibited a high disease burden before HSCT, with 45% experiencing infections in the 6 months before HSCT and 67% exhibiting inflammation. Outcomes in the entire cohort showed a 3-year overall survival, event-free survival (EFS), and grade 3 to 4 graft-versus-host disease (GVHD)-free EFS of 75.9%, 70.2%, and 56.1%, respectively, and were not affected by the type of depletion or age. The cumulative incidence (CI) of primary graft failure (PGF) was 20.6%. The CI of grade 2 to 4 acute GVHD was higher in the PTCY group (P = .04), whereas the CI of grade 3 to 4 GVHD was not. These results indicate that HLA-haploidentical HSCT is a feasible transplant option for patients with CGD lacking HLA-matched donors. Further refinement of transplant protocols is necessary to mitigate graft failure and acute GVHD, ultimately improving access and outcomes for this life-saving therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Riller Q, Hauri M, Lum SH, et al. HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study. Blood. 2025. PMID: 40090009. doi:10.1182/blood.2024026915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。